Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Noxopharm","sponsor":"GenesisCare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Noxopharm Alliance With GenesisCare","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noxopharm Investigating Potential COVID-19 Treatment\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noxopharm Reports Veyonda\u2019s Potential in Late-Stage Cancer at ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noxopharm Reports COVID-19 Trial Program to Commence in Europe","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noxopharm Announces New Research Showing Veyonda\u00ae Cancer Survival Rates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noxopharm Announces First COVID-19 Patient Treated in Veyonda\u00ae Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noxopharm's NOXCOVID Trial Advances to Final Stage","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noxopharm Files Septic Shock Treatment Patent for Veyonda\u00ae","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Data Shows Noxopharm\u2019s Veyonda\u00ae May Prevent Cytokine Storm","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA IND Approval Leads to Breakthrough Testing of Veyonda in First-Line Sarcoma Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noxopharm Confirms Advantage of Combination LuPSMA Therapy in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noxopharm Phase I Clinical Trial Reveals Anti-Inflammatory Response in Patients With COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Noxopharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Noxopharm In-Licenses Novel RNA Technology From Hudson Institute of Medical Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"AUSTRALIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphan Drug Designation Granted to Noxopharm by US FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Noxopharm

    Menu

    Noxopharm

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Noxopharm

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Orphan Drug Designation Granted to Noxopharm by US FDA

              Details:

              The CEP-Program is based on pre-clinical and clinical findings of Veyonda enhancing the anti-cancer effect of a number of standard chemotherapeutic agents. Receiving the ODD will speed up the Company’s commercial development plan for the important US market.

              Lead Product(s): Idronoxil,Doxorubicin Hydrochloride

              Therapeutic Area: Oncology Product Name: Veyonda

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 22, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Noxopharm

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Noxopharm In-Licenses Novel RNA Technology From Hudson Institute of Medical Research

              Details:

              The exclusive global contract aims to maximize opportunities in RNA drug discovery and mRNA vaccine manufacture through Noxopharm’s wholly owned subsidiary, Pharmorage.

              Lead Product(s): mRNA Vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Vaccine

              Recipient: Hudson Institute of Medical Research

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement December 01, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Noxopharm

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Noxopharm Phase I Clinical Trial Reveals Anti-Inflammatory Response in Patients With COVID-19

              Details:

              Veyonda ® is the first drug candidate in the Company's pipeline, which is currently in a Phase 2 clinical trial. Veyonda (idronoxil) is a TBK1 (TANK-binding kinase 1) inhibitor, as an anti-inflammatory in patients with a moderate form of COVID-19.

              Lead Product(s): Idronoxil

              Therapeutic Area: Infections and Infectious Diseases Product Name: Veyonda

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 25, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Noxopharm

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Noxopharm Confirms Advantage of Combination LuPSMA Therapy in Prostate Cancer

              Details:

              This result validates the survival benefit of the same combination seen in a recently completed Phase I/II trial of Veyonda in men with end-stage metastatic castrate-resistant prostate cancer (mCRPC).

              Lead Product(s): Idronoxil,Lutetium-177 Vipivotide Tetraxetan

              Therapeutic Area: Oncology Product Name: Veyonda

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 12, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Noxopharm

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              FDA IND Approval Leads to Breakthrough Testing of Veyonda in First-Line Sarcoma Treatment

              Details:

              IND granted by FDA on evidence that Veyonda may increase generally poor response rates of sarcoma cancers to chemotherapy. The Company has a patent application currently under examination that relates to use of idronoxil in combination with various chemotherapy drugs.

              Lead Product(s): Idronoxil

              Therapeutic Area: Oncology Product Name: Veyonda

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 07, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Noxopharm

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Clinical Data Shows Noxopharm’s Veyonda® May Prevent Cytokine Storm

              Details:

              In a cohort of 18 patients with moderately severe cases of COVID-19, interim data in its NOXCOVID study suggests Veyonda provides protection against progression of the severe inflammation associated with a worsening of the disease.

              Lead Product(s): Idronoxil

              Therapeutic Area: Immunology Product Name: Veyonda

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 27, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Noxopharm

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Noxopharm Files Septic Shock Treatment Patent for Veyonda®

              Details:

              The patent application is aimed at protecting the use of experimental anti-cancer drug, Veyonda® (idronoxil), in blocking the development of septic shock associated with infections such as COVID-19 and influenza viruses.

              Lead Product(s): Idronoxil

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Veyonda

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 14, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Noxopharm

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Noxopharm's NOXCOVID Trial Advances to Final Stage

              Details:

              Part 1 of the NOXCOVID-1 trial involved 26 patients and was a dose-escalation arm testing the safety of increasing (400, 600, 800, 1200, 1800 mg) daily Veyonda dosages.

              Lead Product(s): Idronoxil

              Therapeutic Area: Infections and Infectious Diseases Product Name: Veyonda

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 18, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Noxopharm

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Noxopharm Announces First COVID-19 Patient Treated in Veyonda® Study

              Details:

              The experimental anti-cancer drug, Veyonda®, joins a number of approved and experimental drugs with an anti-inflammatory action being tested globally for their ability to block rapid progression of COVID-19 disease from moderate to severe level.

              Lead Product(s): Idronoxil

              Therapeutic Area: Infections and Infectious Diseases Product Name: Veyonda

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 08, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Noxopharm

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Noxopharm Announces New Research Showing Veyonda® Cancer Survival Rates

              Details:

              The study revealed that in late-stage prostate cancer patients who have exhausted all standard treatment options, a combination of 177Lu-PSMA-617 and Veyonda® is both safe and delivered promising efficacy outcomes, among them a median overall survival of 17.1 months.

              Lead Product(s): Idronoxil,Lutetium-177 Vipivotide Tetraxetan

              Therapeutic Area: Oncology Product Name: Veyonda

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 03, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY